PEGylation of native disulfide bonds in proteins

PEGylation has turned proteins into important new biopharmaceuticals. The fundamental problems with the existing approaches to PEGylation are inefficient conjugation and the formation of heterogeneous mixtures. This is because poly(ethylene glycol) (PEG) is usually conjugated to nucleophilic amine residues. Our PEGylation protocol solves these problems by exploiting the chemical reactivity of both of the sulfur atoms in the disulfide bond of many biologically relevant proteins. An accessible disulfide bond is mildly reduced to liberate the two cysteine sulfur atoms without disturbing the protein's tertiary structure. Site-specific PEGylation is achieved with a bis-thiol alkylating PEG reagent that sequentially undergoes conjugation to form a three-carbon bridge. The two sulfur atoms are re-linked with PEG selectively conjugated to the bridge. PEGylation of a protein can be completed in 24 h and purification of the PEG-protein conjugate in another 3 h. We have successfully applied this approach to PEGylation of cytokines, enzymes, antibody fragments and peptides, without destroying their tertiary structure or abolishing their biological activity.

[1]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[2]  T. Arakawa,et al.  Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed , 1993, Journal of protein chemistry.

[3]  M. Billeter,et al.  MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.

[4]  Darin J. Smith,et al.  A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation. , 2005, Bioconjugate chemistry.

[5]  A. Pavlou,et al.  Recombinant protein therapeutics—success rates, market trends and values to 2010 , 2004, Nature Biotechnology.

[6]  Y. Yoshioka,et al.  Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. , 2003, Nature biotechnology.

[7]  J. Thornton Disulphide bridges in globular proteins. , 1981, Journal of molecular biology.

[8]  D. D. De Souza,et al.  Direct production of proteins with N-terminal cysteine for site-specific conjugation. , 2004, Bioconjugate chemistry.

[9]  Julian B. Chaudhuri,et al.  Refolding of Low Molecular Weight Urokinase Plasminogen Activator by Dilution and Size Exclusion Chromatography—A Comparative Study , 2000 .

[10]  S. Petersen,et al.  Amino acid neighbours and detailed conformational analysis of cysteines in proteins. , 1999, Protein engineering.

[11]  M. Grace,et al.  Site of Pegylation and Polyethylene Glycol Molecule Size Attenuate Interferon-α Antiviral and Antiproliferative Activities through the JAK/STAT Signaling Pathway* , 2005, Journal of Biological Chemistry.

[12]  A. P. Chapman,et al.  PEGylated antibodies and antibody fragments for improved therapy: a review. , 2002, Advanced drug delivery reviews.

[13]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[14]  S. Brocchini,et al.  Molecular Dynamics Simulations of Proteins with Chemically Modified Disulfide Bonds , 2007 .

[15]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[16]  Richard B Greenwald,et al.  Effective drug delivery by PEGylated drug conjugates. , 2003, Advanced drug delivery reviews.

[17]  H. Senn,et al.  Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. , 2005, Bioconjugate chemistry.

[18]  Pinak Chakrabarti,et al.  Disulfide bonds, their stereospecific environment and conservation in protein structures. , 2004, Protein engineering, design & selection : PEDS.

[19]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[20]  Darin J. Smith,et al.  A Long-Acting, Highly Potent Interferon α-2 Conjugate Created Using Site-Specific PEGylation , 2005 .

[21]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[22]  H. Sato,et al.  Enzymatic procedure for site-specific pegylation of proteins. , 2002, Advanced drug delivery reviews.

[23]  Werner Braun,et al.  Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules , 1998, J. Comput. Chem..

[24]  Marianthi Markatou,et al.  Pharmacodynamics of PEG‐IFN α differentiate HIV/HCV coinfected sustained virological responders from nonresponders , 2006, Hepatology.

[25]  H. Scheraga,et al.  Impact of an easily reducible disulfide bond on the oxidative folding rate of multi-disulfide-containing proteins. , 2008, The journal of peptide research : official journal of the American Peptide Society.

[26]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[27]  Yasuo Yoshioka,et al.  Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity , 2003, Nature Biotechnology.

[28]  M. Treuheit,et al.  Mono-N-terminal poly(ethylene glycol)-protein conjugates. , 2002, Advanced drug delivery reviews.

[29]  Alan A. Dombkowski,et al.  Disulfide by DesignTM: a computational method for the rational design of disulfide bonds in proteins , 2003, Bioinform..

[30]  K. Tsumoto,et al.  The effects of arginine on refolding of aggregated proteins: not facilitate refolding, but suppress aggregation. , 2003, Biochemical and biophysical research communications.

[31]  S. Brocchini,et al.  Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. , 2007, Bioconjugate chemistry.

[32]  S. Brocchini,et al.  Site-specific PEGylation of native disulfide bonds in therapeutic proteins , 2006, Nature chemical biology.